Abstract:Activated B-cell-like (ABC)-diffuse large B-cell lymphoma (ABC-DLBCL) is a common subtype of non-Hodgkin's lymphoma with poor prognosis. The survival of ABC-DLBCL relies on constitutive activation of BCR signaling, but the underlying molecular mechanism is not fully addressed. By mining The Cancer Genome Atlas database, we found that the expression of ubiquitin-specific protease 7 (USP7) is significantly elevated in three cancer types including DLBCL. Interestingly, unlike germinal center B-cell-like (GCB)-DLBCL, ABC-DLBCL shows upregulated expression of USP7. Inhibiting the enzymatic activity of USP7 (P22077) has a drastic effect on ABC-DLBCL, but not GCB-DLBCL cells. Compared to GCB-DLBCL, ABC-DLBCL cells show transcriptional upregulation of multiple components of BCR-signaling. USP7 inhibition significantly reduces the expression of upregulated components of BCR signaling. Mechanistically, USP7 inhibition greatly reduces the methylation of histone 3 on lysine 4 (H3K4me2), which is an epigenetic marker for active enhancers. USP7 inhibition greatly reduces the protein level of WDR5 and MLL2, key components of lysine-specific methyltransferase complex (complex of proteins associated with Set1 [COMPASS]). In ABC-DLBCL cells, USP7 stabilizes WDR5 and MLL2. In patients, the expression of USP7 is significantly associated with components of BCR signaling (LYN, SYK, BTK, PLCG2, PRKCB, MALT1, BCL10, and CARD11) and targets of BCR signaling (MYC and IRF4). In summary, we demonstrated an essential role of USP7 in ABC-DLBCL by organizing an oncogenic epigenetic program via stabilization of WDR5 and MLL2. Targeting USP7 might be a novel and efficient approach to treat patients with ABC-DLBCL and it might be better than targeting individual components such as BTK in BCR signaling.

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

Deubiquitinase USP13 Dictates MCL1 Stability and Sensitivity to BH3 Mimetic Inhibitors.

USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses

Deubiquitinase USP9X Stabilizes RNA M6a Demethylase ALKBH5 and Promotes Acute Myeloid Leukemia Cell Survival.

The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization.

Targeting of the deubiquitinase USP9X attenuates B-cell acute lymphoblastic leukemia cell survival and overcomes glucocorticoid resistance.

Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options

SUMOylation of MCL1 protein enhances its stability by regulating the ubiquitin-proteasome pathway

Inhibition of USP1 Reverses the Chemotherapy Resistance Through Destabilization of MAX in the Relapsed/refractory B-cell Lymphoma

USP9X-mediated Deubiquitination of B-cell CLL/lymphoma 9 Potentiates Wnt Signaling and Promotes Breast Carcinogenesis

USP9X destabilizes pVHL and promotes cell proliferation.

Inhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis

Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway

USP14 promotes the malignant progression and ibrutinib resistance of mantle cell lymphoma by stabilizing XPO1

USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma

Inhibition of the Deubiquitinase USP10 Induces Degradation of SYK

USP9X Stabilizes BRCA1 and Confers Resistance to DNA‐damaging Agents in Human Cancer Cells

Suppression of USP7 Induces BCR-ABL Degradation and Chronic Myelogenous Leukemia Cell Apoptosis

The deubiquitinating enzyme OTUD1 antagonizes BH3-mimetic inhibitor induced cell death through regulating the stability of the MCL1 protein

Deubiquitylase USP9X Suppresses Tumorigenesis by Stabilizing Large Tumor Suppressor Kinase 2 (LATS2) in the Hippo Pathway.

The Deubiquitinase USP7 Stabilizes Maf Proteins to Promote Myeloma Cell Survival